IPM Take
Pelacarsen has delivered one of the most useful failures in cardiovascular medicine this year.
For years, the Lp(a) story looked unusually convincing. Elevated lipoprotein(a) is strongly associated with atherosclerotic cardiovascular disease, genetic evidence supports a causal relationship, and pelacarsen had previously lowered Lp(a) by as much as 80% in Phase II testing. The logical next step seemed straightforward: reduce Lp(a), reduce cardiovascular events.
Lp(a)HORIZON has broken that chain of assumptions.
In 8,323 patients with established cardiovascular disease and Lp(a) of at least 70 mg/dL, pelacarsen lowered Lp(a) but did not significantly reduce the trial’s composite endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and urgent coronary revascularisation requiring hospitalisation.
That does not mean Lp(a) has suddenly become a meaningless biomarker. It means the field has reached the point where epidemiology, genetics and biomarker reduction are no longer enough.
Precision medicine eventually has to survive an outcomes trial.
Executive Summary
Lp(a)HORIZON was a global, randomized, double-blind, placebo-controlled Phase III trial involving 8,323 patients with established cardiovascular disease and elevated Lp(a). Participants were eligible with Lp(a) concentrations of at least 70 mg/dL and a history of myocardial infarction, ischaemic stroke or clinically significant peripheral artery disease. They received pelacarsen 80 mg by monthly subcutaneous injection or placebo on top of guideline-directed cardiovascular therapy.
Pelacarsen is an antisense oligonucleotide designed to reduce production of apolipoprotein(a) by targeting LPA messenger RNA in the liver. Earlier Phase II data showed dose-dependent Lp(a) reductions, reaching approximately 80% with the most intensive regimen studied.
On 4 September, Novartis announced that Lp(a)HORIZON had not met its primary endpoint. Although Lp(a) levels were lower with pelacarsen, the reduction did not translate into a statistically significant reduction in cardiovascular events in the overall study population. The company has not yet released the full event numbers, achieved Lp(a) reduction, subgroup analyses or safety dataset from the Phase III trial. Full results are expected at a future medical congress.
The result creates uncertainty for the broader Lp(a)-lowering field. Amgen is testing the siRNA drug olpasiran in the Phase III OCEAN(a)-Outcomes programme, while Lilly’s 17,300-patient ACCLAIM-Lp(a) trial is evaluating the long-acting siRNA lepodisiran. Those agents have produced deeper Lp(a) reductions in earlier studies than pelacarsen, so the Novartis result cannot automatically be extrapolated across the class.
Why it matters
- HTA bodies: Lp(a)HORIZON is a warning against treating biomarker reduction as a surrogate for patient benefit before cardiovascular outcomes are demonstrated. Future assessments of Lp(a)-lowering therapies will need to focus on absolute event reduction, baseline risk, achieved Lp(a) lowering and treatment duration rather than percentage biomarker change alone.
- Payers: If future Lp(a) drugs succeed, this trial will make patient selection even more important. Treating every person with elevated Lp(a) could create enormous budget impact, while the clinically valuable population may ultimately be narrower and defined by baseline Lp(a), established disease, residual risk or treatment timing.
- Industry / innovation partners: Pelacarsen’s failure raises the development bar for olpasiran, lepodisiran and other Lp(a)-targeted programmes. Greater biomarker suppression may help, but the field now needs evidence that deeper or longer suppression produces outcomes that matter to patients.
Few cardiovascular targets arrived at Phase III with a stronger biological argument than lipoprotein(a).
Lp(a) is structurally related to LDL but carries an additional apolipoprotein(a) component. Its concentration is largely genetically determined, remains relatively stable through life and is associated with atherosclerotic cardiovascular disease and aortic valve stenosis. European consensus guidance considers the association with cardiovascular disease causal and recommends that Lp(a) be measured at least once in adulthood.
That combination made Lp(a) unusually attractive for precision prevention.
Unlike smoking, obesity or blood pressure, patients cannot meaningfully lower Lp(a) through lifestyle change. If a genetically determined risk factor could be measured once and directly targeted with an RNA medicine, cardiology would have something close to a textbook precision-medicine pathway: identify a biological risk, suppress its molecular source and prevent the clinical consequence.
Pelacarsen was supposed to provide the final piece of evidence.
The biomarker moved. The outcomes did not.
Lp(a)HORIZON enrolled patients who were already at high cardiovascular risk. All had established cardiovascular disease, and the trial tested whether targeting Lp(a) could reduce residual risk beyond contemporary lipid-lowering, blood-pressure treatment and other guideline-directed care.
The trial’s failure therefore matters because it tested exactly the question the field needed answered.
Pelacarsen lowered Lp(a), but cardiovascular events were not significantly reduced compared with placebo.
The mistake now would be to jump from that result to the claim that Lp(a) is merely a marker rather than a causal factor.
Genetic and epidemiological evidence supporting a causal relationship remains substantial. A negative drug trial can arise for several reasons. The magnitude of Lp(a) reduction may have been insufficient. Treatment may have begun too late, after decades of vascular injury had accumulated. The selected population may have been too heterogeneous. The duration of treatment may have been inadequate. Or the biological effects of Lp(a) may not be fully reversible once advanced atherosclerotic disease is established.
Until the full Lp(a)HORIZON dataset is released, those explanations remain hypotheses.
That uncertainty matters because other companies are approaching the same target differently.
Amgen’s olpasiran uses small interfering RNA and produced reductions above 95% at higher doses in Phase II. Its outcomes programme is ongoing. Lilly’s lepodisiran is also an siRNA therapy, with earlier studies showing sustained Lp(a) suppression around 94%, and its Phase III ACCLAIM-Lp(a) trial plans to enrol approximately 17,300 participants.
If either succeeds, pelacarsen’s failure may ultimately be interpreted as a problem of drug potency, dose, population or timing rather than target biology.
If they fail too, the implications become much larger.
Precision medicine needs clinical endpoints, not just precise biomarkers
Lp(a)HORIZON exposes a recurring weakness in precision medicine: the temptation to confuse biological specificity with clinical certainty.
A therapy can be exquisitely targeted. It can silence the intended gene product, change the intended biomarker and behave exactly as predicted pharmacologically.
Patients can still fail to benefit.
Cardiology has seen versions of this before. Therapies developed around raising HDL cholesterol produced impressive biochemical changes without delivering the expected cardiovascular protection. In some cases, apparently compelling observational relationships did not survive randomized trials.
Lp(a) is not identical to HDL because its causal evidence is much stronger, but the governing principle is the same.
A biomarker earns clinical importance when acting on it improves outcomes, not merely when it predicts them.
That makes the full Lp(a)HORIZON results unusually important for regulators, HTA agencies and companies developing the next wave of RNA therapies. They will need to understand not simply whether pelacarsen failed, but where the treatment effect disappeared.
Was there a signal among patients with the highest Lp(a)? Did greater achieved lowering matter? Did duration or baseline disease burden change the response? Was the event curve completely neutral or did it separate too late?
Those questions cannot be answered from the topline announcement.
For now, the most defensible conclusion is narrower.
Lp(a) remains an important inherited cardiovascular risk factor. Pelacarsen lowered it. But in this large Phase III trial, lowering it with this treatment strategy was not enough to reduce cardiovascular events.
Precision cardiology now has to find out why.
